Bronchiectasis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Bronchiectasis – Pipeline Review, H1 2017’, provides an overview of the Bronchiectasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bronchiectasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bronchiectasis

The report reviews pipeline therapeutics for Bronchiectasis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bronchiectasis therapeutics and enlists all their major and minor projects

The report assesses Bronchiectasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bronchiectasis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bronchiectasis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bronchiectasis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alitair Pharmaceuticals Inc

Bayer AG

Chiesi Farmaceutici SpA

GlaxoSmithKline Plc

Grifols SA

Insmed Inc

Kamada Ltd

Polyphor Ltd

Recipharm AB

Vertex Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bronchiectasis - Overview

Bronchiectasis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Bronchiectasis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bronchiectasis - Companies Involved in Therapeutics Development

Alitair Pharmaceuticals Inc

Bayer AG

Chiesi Farmaceutici SpA

GlaxoSmithKline Plc

Grifols SA

Insmed Inc

Kamada Ltd

Polyphor Ltd

Recipharm AB

Vertex Pharmaceuticals Inc

Bronchiectasis - Drug Profiles

alpha-1 proteinase inhibitor (human) second generation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amikacin sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARD-3150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CHF-6333 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ciprofloxacin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

doxofylline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erdosteine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2269557 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INS-1007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

POL-6014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VX-371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bronchiectasis - Dormant Projects

Bronchiectasis - Discontinued Products

Bronchiectasis - Product Development Milestones

Featured News & Press Releases

May 03, 2017: Insmed Provides Update On Phase 2 Study Of INS1007

Dec 01, 2016: Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections with Pseudomonas aeruginosa

Oct 18, 2016: Multi-million Dollar DTRA Funding for Biodefense Research with Aradigm Inhaled Ciprofloxacins

Oct 18, 2016: Bayer to Present Data in Non-Cystic Fibrosis Bronchiectasis at the 2016 Annual Meeting of the American College of Chest Physicians

Sep 22, 2016: Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients

Mar 17, 2016: Aradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency

Jan 05, 2016: Aradigm to Host Corporate Update Conference Call on January 6

Oct 13, 2015: Aradigm Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis

Sep 22, 2015: Aradigm Completes Enrollment in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)

Apr 16, 2015: Aradigm to Host Key Opinion Leader Breakfast and Webcast on April 23 in New York City

Jan 14, 2015: Aradigm Granted Key Composition of Matter Patents for Pulmaquin in Europe and Australia

Nov 24, 2014: FDA Grants QIDP Designation to Bayer's Ciprofloxacin Dry Powder for Inhalation

Sep 04, 2014: FDA Grants Fast Track Designation to Aradigm’s Pulmaquin for Non-Cystic Fibrosis Bronchiectasis

Jun 23, 2014: Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)

Jun 03, 2014: Aradigm Receives $5 Million Milestone For Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Bronchiectasis, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Bronchiectasis – Pipeline by Alitair Pharmaceuticals Inc, H1 2017

Bronchiectasis – Pipeline by Bayer AG, H1 2017

Bronchiectasis – Pipeline by Chiesi Farmaceutici SpA, H1 2017

Bronchiectasis – Pipeline by GlaxoSmithKline Plc, H1 2017

Bronchiectasis – Pipeline by Grifols SA, H1 2017

Bronchiectasis – Pipeline by Insmed Inc, H1 2017

Bronchiectasis – Pipeline by Kamada Ltd, H1 2017

Bronchiectasis – Pipeline by Polyphor Ltd, H1 2017

Bronchiectasis – Pipeline by Recipharm AB, H1 2017

Bronchiectasis – Pipeline by Vertex Pharmaceuticals Inc, H1 2017

Bronchiectasis – Dormant Projects, H1 2017

Bronchiectasis – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Bronchiectasis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports